Multiple Myeloma Clones are Derived from a Cell Late in B Lymphoid Development

Abstract

We have previously demonstrated that the immunoglobulin (Tg) heavy chain variable region (VH) sequences expressed by the malignant clone in multiple myeloma (MM) contain a high degree of somatic mutation without clonal diversity. This sequence can be used to identify all members of the malignant clone in this B cell malignancy. We sequenced the variable regions expressed by patients with MM and generated primers from the complementarity determining region (CDR) sequences specific for each patient’s tumor. Using these primers, we performed PCR amplification on highly purified subpopulations of cells separated by expression of CD 10, CD34 and CD38. The results of these experiments demonstrate: 1) there is a small fraction of CDlO-expressing tumor cells in MM patients, 2) CD34-bearing malignant cells do not exist in MM, and 3) although the vast amount of tumor is in the CD38-expressing cells, a small amount of tumor is in the CD38-negative population. We also used these primers to determine whether pre-class switch (i.e., Cµ.-expressing lymphocytes) clonal cells exist in these patients. After PCR amplification with CDR1 and Cµ primers, colony hybridization was performed using both framework 3 (FR3) and CDR3 probes. Out of >200 FR3-hybridizing colonies, ≤ 5 colonies also hybridized with the CDR3 probe. Colonies which hybridized with both these probes were sequenced, and none of these sequences matched even closely the CDR3 expressed by the malignant clone. These results make the existence of a pre-class switch malignant cell unlikely in MM. Overall, these results suggest that the malignant clone in MM derives from a cell late in B lymphocyte development.